为研究复合乳杆菌（鼠李糖乳杆菌LrGG-100、长双岐杆菌CP-9、嗜酸乳杆菌LA-99和干酪乳杆菌LC-88）对慢传输型便秘小鼠的缓解作用。使用盐酸洛哌丁胺作为便秘小鼠造模药物。将雄性BALB/c小鼠随机分成健康组、便秘组、阳性组、复合乳杆菌低、高剂量组；灌胃相应内容物21 d后，处死小鼠取样，测定小鼠小肠推进率等胃肠道功能指标、血清细胞因子水平、胃肠调节肽含量以及AQP3和c-kit的转录水平。结果显示，与便秘组相比，复合乳杆菌低、高剂量组的小肠推进率显著提高61.45%（p<0.05）、1.22倍（p<0.05），排便时间缩短21.42%（p<0.05）、29.14%（p<0.05），排便数量增加1.50倍（p<0.05）、1.52倍（p<0.05），排便质量增加1.13倍（p<0.05）、1.25倍（p<0.05）；高剂量组的AQP3和c-kit基因转录水平分别是便秘组的1.82倍（p<0.05）和2.00倍（p<0.05）；灌胃复合乳杆菌能够增加血清中P物质和胃动素含量，降低血清血管活性肠肽、生长抑素和内皮素-1含量。复合乳杆菌能有效缓解便秘症状，其作用可能与胃肠调节肽水平以及AQP3和c-kit的表达有关。

To explore the relieving effect of compound Lactobacillus (Lactobacillus rhamnosus LrGG-100, Bifidobacterium longum CP-9, Lactobacillus acidophilus LA-99 and Lactobacillus casei LC-88) for slow transit constipation in mice, loperamide hydrochloride was used to establish a mouse model of constipation. Male BALB/c mice were randomly divided into the healthy group, constipation group, positive group, and low- and high-dose compound lactobacillus groups. After 21 days of gavage with corresponding contents, the mice were sacrificed for sampling, and their gastrointestinal function indicators such as the small intestine propulsion rate, levels of secreted serum cytokines, contents of gastrointestinal regulatory peptides, and transcription levels of AQP3 and c-kit were measured. The results showed that compared with the constipation group, the low- and high-dose compound lactobacillus groups had higher small intestine propulsion rate (increased by 61.45%, p<0.05; 1.22 times, p<0.05), shortened defecation time (decreased by 21.42%, p<0.05; 29.14%, p<0.05), increased number of defecation (increased by 1.5 times p<0.05; 1.52 times, p<0.05), and increased weight of stool (increased by 1.13 times, p<0.05; 1.25 times, p<0.05) in, the transcription levels of AQP3 and c-kit genes of the high-dose group were 1.82 times (p<0.05) and 2.00 times (p<0.05), respectively, those of the constipation group. Intragastric administration of compound Lactobacillus could increase the contents of substance P and motilin in the serum, and decrease the contents of vasoactive intestinal peptides, somatostatin and endothelin-1. Compound Lactobacillus could alleviate constipation symptoms. This effect may be related to the level of gastrointestinal regulatory peptides and the expressions of AQP3 and c-kit.